The Latest Breaking News from Invitae

Money and lobbying help shield lab-developed tests, including prenatal screenings, from heightened federal scrutiny

Upgrades

According to Benzinga Pro data, during Q1, Invitae (NYSE:NVTA) posted sales of $123.69 million. Earnings were up 11.34%, but Invitae still reported an overall loss of $181.86 million.

Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:

Invitae's (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around the stock. However, given the company's widening losses and poor profitability, the question is, is it worth betting on the stock at the…

Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.

Over the past 3 months, 4 analysts have published their opinion on Invitae (NYSE:NVTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Invitae Corp's (NASDAQ: NVTA)